News

Zealand Pharma Faces Setback After FDA Rejects Treatment Proposal

Zealand Pharma Faces Setback After FDA Rejects Treatment Proposal

Zealand Pharma's Latest Challenge with FDA Approval

Zealand Pharma has encountered a significant obstacle as its shares took a steep decline following the U.S. Food and Drug Administration's (FDA) refusal to approve the company’s treatment for bowel disease. This decision requires further trials to confirm the drug’s safety and efficacy, reflecting the rigorous standards the FDA maintains for new treatments.

Impact on Zealand Pharma's Stock Performance

After the FDA announcement, Zealand Pharma (NASDAQ: ZEAL) witnessed its stock drop by over 10% during European trading hours. The investor community responded swiftly, indicating a clear concern regarding the drug's future prospects in the market.

FDA's Concerns and Additional Trials

According to the FDA's complete response letter, Zealand Pharma's submission lacked sufficient evidence to support the assertion that the proposed dosage of glepaglutide was both safe and effective. This latest setback marks the second significant regulatory challenge for the Danish biotech firm, following a previous rejection of its treatment aimed at low blood sugar in infants.

Understanding Glepaglutide's Purpose

Glepaglutide was specifically developed to assist adults suffering from short bowel syndrome (SBS) and intestinal failure who rely on parenteral nutrition—administering necessary nutrients directly into the bloodstream. SBS is a rare condition that severely impacts the small intestine's ability to absorb vital nutrients, with around 7,500 cases reported among adults in the United States, based on company estimates.

Clinical Research Insights

In late-stage clinical trials, glepaglutide when given twice a week resulted in a notable decrease in the dependency on parenteral support when compared to a placebo. However, the once-weekly dosage, although it also reduced the need for parenteral support, did not present statistically significant results.

Next Steps for Zealand Pharma

Despite this hurdle, Zealand Pharma is committed to continuing discussions with the FDA to explore the necessary steps for obtaining regulatory approval in the U.S. Moreover, the company has plans to launch a late-stage clinical trial in the near future, set for 2025. This trial is designed to strengthen regulatory submissions for glepaglutide in additional markets, particularly in Europe.

Market Potential and Analyst Predictions

Analysts at Jefferies have suggested that glepaglutide could achieve peak global sales reaching up to $600 million. They estimate a net present value (NPV) of around 90 Danish kroner per share, with an assumed 8% discount rate and a 90% probability of success. This analysis hints at a potential mid-single-digit percentage downside for the stock in the near term.

Investor Sentiment and Future Outlook

Despite the current challenges, some analysts maintain that there are potential rewards to be realized. They believe that there are opportunities to explore amidst the volatility in the stock’s performance, particularly in light of upcoming data from another pipeline drug.

Frequently Asked Questions

What caused Zealand Pharma's stock to drop?

The stock fell sharply after the FDA rejected the company's treatment for bowel disease, requesting further trials for safety and efficacy.

What is glepaglutide designed to treat?

Glepaglutide is developed to treat adults with short bowel syndrome and intestinal failure who need parenteral nutrition.

Are there future plans for glepaglutide?

Yes, Zealand Pharma plans to conduct a late-stage clinical trial in 2025 to support regulatory applications in various markets.

What do analysts predict about glepaglutide's sales potential?

Analysts project a global peak sales potential of approximately $600 million for glepaglutide.

How are investors reacting to Zealand Pharma's recent setbacks?

While some analysts see risks, others view the current stock performance as a possible buying opportunity, anticipating future prospects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 99

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Veterans United Foundation Marks 15 Years of Giving

Updated Category News Views 0

A Milestone Measured in More Than Checks Fifteen years can turn a workplace charity into background noise, but this one plainly has not drifted into autopilot. Veterans United Foundation closed its 2026 anniversary campaign, called The Good Goes On, with $1.5 million directed to charitable organizations, 1,145 employee volunteers, and 2,680 hours of hands-on work. That is...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 52

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 305

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 319

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 24

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 13

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 92

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 225

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading

Top 5 Most Recently Viewed Articles

AEA Private Debt's Strategic Investment in Weller Metalworks

Updated Category News Views 299

Let's cut to the chase: AEA Private Debt is making some serious waves in the middle market with its latest move as the Sole Provider of mezzanine notes for Weller Metalworks' acquisition of DROP Sprockets, Inc. This isn’t just another deal; it’s a calculated step in an increasingly competitive landscape where metal fabrication firms are vying for supremacy. Weller...

Continue Reading
Medication Management Partners Continues to Excel in Senior Care

Updated Category News Views 196

Medication Management Partners Earns Prestigious Recognition In recent news, Medication Management Partners (MMP), a leading long-term care pharmacy, proudly announces its place on the Inc. 5000 list of fastest-growing private companies in America for the seventh consecutive year. This achievement signifies the company’s steady growth and innovative practices in the...

Continue Reading
AlphaGen Unveils Major Expansion Plans for Power Generation

Updated Category News Views 501

AlphaGen's Ambitious 450 MW Power Generation Initiative Alpha Generation, LLC ("AlphaGen"), based in Stamford, Conn., is taking a significant step towards meeting the escalating demand for reliable electric power across the nation. With plans to add approximately 450 megawatts (MW) of additional electric generation at four existing power stations, AlphaGen aims to bolster...

Continue Reading
STAT Secures a Loeb Award for Outstanding Reporting on Opioids

Updated Category News Views 185

STAT Achieves Recognition for Vital Reporting STAT addiction reporter Lev Facher has been honored with a 2025 Loeb Award for his exceptional work in explanatory reporting. This award, regarded as the pinnacle of accomplishment in business and financial journalism, recognizes Facher's six-part series titled "The War on Recovery." The compelling series sheds light on the...

Continue Reading
Investigation into Nomura Holdings, Inc. Sparks Investor Concerns

Updated Category News Views 67

Introduction to the Investigation of Nomura Holdings, Inc. Pomerantz LLP is currently conducting an investigation focused on claims made on behalf of investors of Nomura Holdings, Inc. (NYSE: NMR). The essence of this investigation revolves around whether Nomura and some of its key officers or directors may have engaged in securities fraud or other illicit business...

Continue Reading